Active, Not Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04812925
- Conditions
- Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
- Locations
-
- Investigator Site 0010116 Bentonville, Arkansas, United States
- Investigator site 0010045 Washington D.C., District of Columbia, United States
- Investigator Site 0010062 Fort Wayne, Indiana, United States
- Investigator site US0010042 Iowa City, Iowa, United States